United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $547.91, for a total transaction of $5,205,145.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,197,477.83. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $540.05 on Wednesday. The company has a market capitalization of $22.93 billion, a PE ratio of 19.94, a P/E/G ratio of 1.77 and a beta of 0.57. The company has a 50-day simple moving average of $566.86 and a two-hundred day simple moving average of $516.87. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.63 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. UBS Group upped their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the company. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC boosted its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.